Drugs / Methylcantharidimide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03996681 | Jul 2019 → Jul 2020 | hepatocellular carcinoma | Suzhou Municipal Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methylcantharidimide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03996681 ↗ |
| Modality | Small molecule | “Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.” NCT03996681 ↗ |
| Route | Oral | “Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment.” NCT03996681 ↗ |